Winners and losers at #EHA18: Shares mostly slide as data from a range of prominent biotechs fail to wow investors
News is pouring out of Stockholm, Sweden Friday morning as the annual meeting for the European Hematology Association gets fully underway. The conference, which attracts something like 10,000 hematologists, is on its second day — and many of this year’s newsmakers are working in the competitive field of blood cancers.
Bluebird arrived with their latest incremental update on LentiGlobin, with data from several studies, but it couldn’t hold on to early gains today as the crowd of onlookers played tough with the biotech shares on the line today. You can see the full story on bluebird here; the summary of the rest lies below:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.